Vision and Mission

We are a pioneering biopharmaceutical company developing novel, effective therapeutics addressing the root cause of Alzheimer’s disease and other neurodegenerative disorders.

Our breakthrough discovery on the gene regulatory function of the key genetic variants has uncovered the “true disease-causing factors” and provided new, unexploited molecular targets for small molecules discovery programs.

The Selonterra Value Proposition

Rooted in human genetics


De-risking translation to humans

Unexploited mechanisms


Differentiated, competitive advantage

Targeted patient population


Rational selection of trial participants

Small molecule drugs


Patient convenience, Market advantage

Unique Approach

Our groundbreaking research addresses the root cause of neurodegenerative diseases.

  • Genetic variants cause neurodegeneration


  • The DNA change in its genomic environment causes disease


  • This in turn changes gene expression nearby


  • True disease genes – entirely unexploited targets

Single nucleotide polymorphism



Nucleotide repeat expansion



The Selonterra Platform

Effective Drugs

Development of orally available, disease modifying therapies

Drug Development

Small molecule discovery program

Disease Pathway

Identification of molecular route from target to disease


Strong, compelling genetic links to neurodegenerative diseases


Genetic variants control the expression of genes nearby


Those genes are the true disease-causing factors


Our Platform creates a rich Pipeline across Neurodegenerative Disorders

Drug Development
Drug Development
Target Validation
Drug Development
Lead Optimization
In Vivo POC
Drug Development
Drug Development
Phase 1 with POC
  • Alzheimer’s Disease (APOE4)
  • Parkinson’s Disease (SNCA A53T, LRRK2 G2019S)
  • ALS / FTD (C9orf72 Repeat Expansion)
  • Alzheimer’s Disease (Familial mutations)

Alzheimer’s disease

We have developed small molecule modulators of our novel, unexploited, highly druggable target. Our lead compounds restore APOE4-induced gene expression dysfunction and synaptic deficits. We are poised to rapidly move through lead optimization to IND-enabling studies.

Parkinson’s disease

Important genetic contributors to Parkinson’s disease are variants of the SNCA and LRRK2 genes. We have identified novel drug targets with dysregulated expression levels in human neurons carrying PD associated gene variants.

Extended indications

We pursue complementary programs for the therapy of ALS caused by nucleotide repeat expansions in C9orf72 and single nucleotide variants in familial AD (APP mutations). Orphan indications offer an additional regulatory protection for a development compound.